Patent details

LUC00297 Product Name: Vutrisiran sous toutes les formes protégées par le brevet de base

Basic Information

Publication number:
LUC00297
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP167505676
Legal Status:
Inactive
Application number:
LUC00297
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/22/1681
Marketing Authorization Type:
Marketing Authorization Date:
16/09/2022
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
06/02/2023
First Marketing Authorization date:
16/09/2022
Grant date:
22/09/2025
Activation date:
Publication date:
07/02/2023
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
16/09/2037
SPC Extension Expiration:
16/09/2037
Rejection date:
Withdrawal date:

Owner

From:
06/02/2023
 
 

Name:
Alnylam Pharmaceuticals, Inc.
Address:
300 Third Street, 3rd Floor, Cambridge, MA 02142, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
06/02/2023
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2023/03
Publication date:
01/03/2023
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2025/11
Publication date:
02/10/2025
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/07/2036
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
06/02/2023 Application Form 3
06/02/2023 MA publication 2
07/02/2023 Outgoing Correspondence 1
06/02/2023 Summary of the product caracteristics 31
06/02/2023 Marketing authorization 3
06/02/2023 General Document 3
07/02/2023 Publication 1
22/09/2025 Publication 1
22/09/2025 Certificate 1
22/09/2025 Outgoing Correspondence 1